Biobased and Renewable Products Update
October 3, 2019
DOE Announces Funding For Bioenergy R&D Projects
On October 1, 2019, the U.S. Department of Energy (DOE) announced that 35 projects have been selected to receive funding for bioenergy research and development (R&D). Totaling $73 million in funding provided by DOE’s Office of Energy Efficiency and Renewable Energy (EERE), the selected projects aim to:
- Reduce the price of drop-in biofuels;
- Lower the cost of biopower; and
- Enable high-value products from biomass or waste resources.
According to DOE, the United States has the potential to produce 1 billion dry tons of non-food biomass without the disruption of agricultural markets for food and animal feed. These domestic resources, however, are currently underutilized. Given these circumstances, the main goal of the 35 selected projects will be to produce affordable biofuels that are compatible with the existing fueling infrastructure and vehicles in a range of transportation modes.
LLNL To Host Webinar On HPC4EI Program
On September 30, 2019, DOE announced that the Lawrence Livermore National Laboratory (LLNL) will host an informational webinar about the High Performance Computing for Energy Innovation (HPC4EI) Program. In honor of National Manufacturing Day, the webinar is scheduled for October 4, 2019, at 12:00 p.m. (EDT). The HPC4EI Program pairs national laboratory scientists with partners in industry to apply high-performance computing technology and improve energy utilization in the manufacturing sector. Eighty-four projects currently exist under the HPC4EI Program, encouraging National Laboratories’ and industry collaboration to speedily bring these technologies to market. The 84 projects underway involve nine participating laboratories and are working to address problems in a variety of industries, including metal smelting, additive manufacturing, alloy design, mobility, pulp and paper production, and paint application. The LLNL webinar will include an overview of the HPC4EI Program and its impact followed by presentations by principal investigators on the progress of specific projects.
DOE SBIR/STTR Programs Office Opens Applications For The Cohort of Innovators
On September 30, 2019, DOE’s Smart Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs Office announced the opening of applications for Cohort of Innovators through October 31, 2019. Three DOE National Laboratories are accepting such applications: (1) Argonne National Laboratory (ANL) Chain Reaction Innovation; (2) Oak Ridge National Laboratory (ORNL) Innovation Crossroads; and (3) Lawrence Berkeley National Laboratory (LBL) Cyclotron Road program. Each of the programs recruits a cohort of entrepreneurial scientists and engineers from around the world for two years. The goal of the programs is to allow innovators to mature their ideas until they can align with the most suitable commercial partners to take their technology to scale. Selected participants will receive a two-year fellowship, which includes a stipend depending on education and experience, along with health insurance and a travel allowance. Research funding and access to research facilities, equipment, and expertise are also provided, accompanied by a startup curriculum and a community of peers. The startup curriculum includes intensive entrepreneurial training, mentorship, and networking opportunities. Again, applications are due by October 31, 2019, and can be found in the National Laboratories’ respective websites: ANL, ORNL, and LBL.
FDA Announces Availability Of Draft Guidance On Bioequivalency For Soluble Powder Oral Dosage Form Products And Type A Medicated Articles
The U.S. Food and Drug Administration (FDA), on September 30, 2019, announced the availability of a draft guidance for industry (GFI) #171 titled “Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Manufactured from Active Pharmaceutical Ingredients Considered to be Soluble in Aqueous Media.” The draft GFI describes how EPA intends to evaluate requests for waiving the requirement for performing in vivo bioequivalence studies for animal drugs administered orally as soluble powders or as Type A medicated articles manufactured from active pharmaceutical ingredients considered to be soluble in aqueous media. EPA is accepting comments on the draft GFI until November 29, 2019, before it starts working on the final version of it.
Biobased and Renewable
Products Advocacy Group
2200 Pennsylvania Ave., N.W.
Washington, D.C. 20037